Cargando…
Progress of research on molecular targeted therapies for colorectal cancer
Colorectal cancer (CRC) is one of the most common malignancies, accounting for approximately 10% of global cancer incidence and mortality. Approximately 20% of patients with CRC present metastatic disease (mCRC) at the time of diagnosis. Moreover, up to 50% of patients with localized disease eventua...
Autores principales: | Huang, Shilin, Ye, Jiazhou, Gao, Xing, Huang, Xi, Huang, Julu, Lu, Lu, Lu, Cheng, Li, Yongqiang, Luo, Min, Xie, Mingzhi, Lin, Yan, Liang, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443711/ https://www.ncbi.nlm.nih.gov/pubmed/37614311 http://dx.doi.org/10.3389/fphar.2023.1160949 |
Ejemplares similares
-
Homologous Recombination Pathway Alternation Predicts Prognosis of Colorectal Cancer With Chemotherapy
por: Lin, Yan, et al.
Publicado: (2022) -
Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma
por: Ye, Jiazhou, et al.
Publicado: (2022) -
RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5
por: Gao, Xing, et al.
Publicado: (2023) -
A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
por: Huang, Julu, et al.
Publicado: (2023) -
Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma
por: Lin, Yan, et al.
Publicado: (2022)